Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.

Pharmacogenetics and genomics - 1 Jan 2014

de Keyser Catherine E, Peters Bas J M, Becker Matthijs L, Visser Loes E, Uitterlinden André G, Klungel Olaf H, Verstuyft Céline, Hofman Albert, Maitland-van der Zee Anke-Hilse, Stricker Bruno H

Abstract excerpt

OBJECTIVE: The SLCO1B1 c.521T>C polymorphism is associated with statin plasma levels and simvastatin-induced adverse drug reactions. We studied whether the c.521T>C polymorphism is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin t...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Atorvastatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heptanoic Acids

Share to Liver-Specific Organic Anion Transporter 1

Share to Organic Anion Transporters

Share to Pyrroles

Share to Simvastatin

Share to Thymine

Source

Identifiers

PMID: 24263182
DOI: 10.1097/FPC.0000000000000018

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24263182-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.PMID 24263182Read ↗

Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.Semantic proximity Read ↗

Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users.Semantic proximity Read ↗

Predictive value of<i>SLCO1B1</i>c.521T>C polymorphism on observed changes in the treatment of 1136 statin-usersSemantic proximity Read ↗

Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy.Semantic proximity Read ↗

Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variantsSemantic proximity Read ↗

Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins.Semantic proximity Read ↗

Association between genetic variation in the ABCB1 gene and switching, discontinuation, and dosage of antidepressant therapy: results from the Rotterdam Study.Semantic proximity Read ↗

No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.Semantic proximity Read ↗

Statin treatment effectiveness and the <i>SLCO1B1</i>*5 reduced function genotype: long-term outcomes in women and menSemantic proximity Read ↗

The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin.Semantic proximity Read ↗

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.Semantic proximity Read ↗

Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.